Tygacil misses diabetic foot ulcer endpoint

Wyeth (NYSE:WYE) said Tygacil tigecycline missed the primary endpoint in a Phase III trial to treat diabetic foot ulcers. Further details were not disclosed. The IV glycylcycline antibiotic is approved to treat community-acquired pneumonia (CAP) in the U.S. and complicated skin and skin structure infections (cSSSIs) and complicated intra-abdominal infections in the U.S., EU, and several other countries. ...